Newly diagnosed acute promyelocytic leukemia: Arsenic moves front and center

Journal of Clinical Oncology

Volumn 29, Issue 20, 2011, Pages 2743-2746

  Estey, Elihu H ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ARSENIC TRIOXIDE; CYTARABINE; DAUNORUBICIN; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; RETINOIC ACID;

CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RELAPSE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; EDITORIAL; HUMAN; LEUKOCYTE COUNT; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; TREATMENT FAILURE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; DEVELOPING COUNTRIES; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; OXIDES; SURVIVAL ANALYSIS; TRETINOIN;

EID: 79960269272     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.1031     Document Type: Editorial

References (25)

1. Ghavamzadeh A, Alimoghaddam K, Shahrbano R, et al: Phase II study of single agent arsenic trioxide for the frontline therapy of acute promyelocytic leukemia. J Clin Oncol 29:2753-2757, 2011
2. Soignet SL, Frankel SR, Douer D, et al: United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19:3852-3860, 2001 (Pubitemid 32880064)
3. Mathews V, George B, Lakshmi KM, et al: Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Durable remissions with minimal toxicity. Blood 107:2627-2632, 2006
4. Mathews V, George B, Chendamarai E, et al: Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Long-term follow-up data. J Clin Oncol 28:3866-3871, 2010
5. Lo-Coco F, Avvisati G, Vignetti M, et al: Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: Results of the AIDA-2000 trial of the GIMEMA Group. Blood 116:3171-3179, 2010
6. Sanz MA, Montesinos P, Rayón C, et al: Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: Further improvements in treatment outcome. Blood 115:5137-5146, 2010
7. Adès L, Chevret S, Raffoux E, et al: Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol 24:5703-5710, 2006 (Pubitemid 46631312)
8. Ades L, Raffoux E, Chevret S, et al: Is AraC required in the treatment of standard risk APL? Long term results of a randomized trial (APL 2000) from the French Belgian Swiss APL Group. Blood 116:11, 2010 (suppl; abstr 13)
9. Powell BL, Moser B, Stock W, et al: Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 116:3751-3757, 2010
10. Sanz MA, Grimwade D, Tallman MS, et al: Management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 113:1875-1891, 2009
11. Adès L, Guerci A, Raffoux E, et al: Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: The European APL Group experience. Blood 115:1690-1696, 2010
12. Tsimberidou AM, Tirado-Gomez M, Andreeff M, et al: Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: An update of The University of Texas M. D. Anderson Cancer Center Series. Leuk Lymphoma 47:1062-1068, 2006
13. Shen ZX, Shi ZZ, Fang J, et al: All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 101:5328-5335, 2004 (Pubitemid 38481160)
14. Ravandi F, Estey E, Jones D, et al: Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 27:504-510, 2008
15. Estey EH, Giles FJ, Beran M, et al: Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 99:4222-4224, 2002 (Pubitemid 35332070)
16. Lo-Coco F, Cimino G, Breccia M, et al: Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 104:1995-1999, 2004
17. Ravandi F, Estey EH, Cortes JE, et al: Phase II study of all-trans retinoic acid, arsenic trioxide, with or without gemtuzumab ozogamicin for the frontline therapy of patients with acute promyelocytic leukemia. Blood 116:472, 2010 (suppl; abstr 1080)
18. Montesinos P, González JD, González J, et al: Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic acid and anthracycline-based chemotherapy. J Clin Oncol 28:3872-3879, 2010
19. Breccia M, Latagliata R, Cannella L, et al: Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: Association with high WBC count, late diagnosis and delayed treatment initiation. Haematologica 95:853-854, 2010
20. Tallman MS, Manji GA: Don't just stand there, do something: Strategies for the prevention of early death in acute promyelocytic leukemia - A commentary. Blood Cells Mol Dis 46:173-174, 2011
21. Dyck JA, Warrell RP Jr, Evans RM, et al: Rapid diagnosis of acute promyelocytic leukemia by immunohistochemical localization of PML/RAR-alpha protein. Blood 86:862-867, 1995
22. Jácomo RH, Melo RA, Souto FR, et al: Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica 92:1431-1432, 2007 (Pubitemid 350144166)
23. Park JH, Panageas KS, Schymura MJ, et al: A population-based study in acute promyelocytic leukemia (APL) suggests a higher early death rate and lower overall survival than commonly reported in clinical trials: Data from the Surveillance, Epidemiology, and End Results (SEER) Program and the New York State Cancer Registry in the United States between 1992-2007. Blood 116:382, 2010 (suppl; abstr 872)
24. Au WY, Kumana CR, Kou M, et al: Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood 102:407-408, 2003 (Pubitemid 36759684)
25. Siu CW, Au WY, Yung C, et al: Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: Implications for longterm cardiac safety. Blood 108:103-106, 2006 (Pubitemid 43990617)